Cargando…
Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn’s Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability
Antibodies directed to tumour necrosis factor-α (TNF-α) are very effective in treating paediatric Crohn’s disease (CD). Over the last few years, research has provided important new insights into how to optimise this treatment’s effectiveness. Research on predictors for anti-TNF treatment responsiven...
Autores principales: | Cozijnsen, M. A., Samsom, J. N., de Ridder, L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775976/ https://www.ncbi.nlm.nih.gov/pubmed/29079905 http://dx.doi.org/10.1007/s40272-017-0266-9 |
Ejemplares similares
-
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
por: Kim, HoUng, et al.
Publicado: (2020) -
Biosimilar Uptake: The Importance of Healthcare Provider Education
por: Oskouei, Sonia Tadjalli, et al.
Publicado: (2021) -
Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial
por: Cozijnsen, M A, et al.
Publicado: (2016) -
Multiple Switches From the Originator Infliximab to Biosimilars Is Effective and Safe in Inflammatory Bowel Disease: A Prospective Multicenter Cohort Study
por: Hanzel, Jurij, et al.
Publicado: (2021) -
Reclaiming the systems approach to paediatric safety
por: Cheung, Ronny, et al.
Publicado: (2019)